Trial Profile

A Phase II Study of Tesetaxel Administered at a Flat Dose Once Every 21 Days as Second-line Therapy to Subjects With Advanced Gastric Cancer.

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 05 Aug 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tesetaxel (Primary)
Indications Gastric cancer
Focus Adverse reactions; Therapeutic Use

Most Recent Events

16 Mar 2012 Planned number of patients changed from 27 to 54 as reported by M.D. Anderson Cancer Center record.
16 Mar 2012 New source identified and integrated (2009-0995; M.D. Anderson Cancer Center).
12 Mar 2012 Planned End Date changed from 1 Apr 2012 to 1 Oct 2012 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com